Global Psoriatic Arthritis (PsA) Treatment Industry is poised to culminate in US$ 15.6 Billion by 2028, driven by innovation and a focus on patients | FMI

Psoriatic Arthritis (PsA) Treatment Industry

In 2022, the psoriatic arthritis (PsA) treatment industry size is expected to generate sales of more than US$ 10.3 billion. By 2028, the market size is anticipated to reach US$ 15.6 billion, growing at a strong 7.1% CAGR. Furthermore, small molecule targeted therapies have also emerged as a valuable addition to the treatment arsenal. Janus kinase (JAK) inhibitors are one such class of drugs that have shown promising results in managing PsA symptoms. These medications interfere with specific signaling pathways involved in inflammation, providing patients with alternative options for controlling their condition.

In recent years, the psoriatic arthritis (PsA) treatment market has seen tremendous expansion and innovation, driven by developments in medical research and a rising consciousness of psoriatic arthritis among patients and healthcare professionals. Psoriatic arthritis is a long-term autoimmune disorder that damages joints and causes inflammation in people who have psoriasis. New medicines that focus on the underlying immunological dysfunction and inflammation linked to PsA have changed the market for treating the disorder.

Get Sample Copy of Latest Reports! https://www.futuremarketinsights.com/reports/sample/rep-gb-2718

Nonsteroidal anti-inflammatory medicines (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) were used in traditional PsA treatments in an effort to reduce symptoms and limit the disease’s progression. However, the effectiveness and potential adverse effects of these solutions were frequently constrained. The landscape of PsA treatment has undergone a transformation in recent years thanks to a new generation of targeted biologic medicines. By directly targeting molecules implicated in the immune response, these biologics—such as TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors—offer more precise mechanisms of action.

The PsA treatment market is not only focusing on symptom relief and disease management but also on improving patients’ overall quality of life. Patient-centric approaches have led to the development of therapies that address not only joint symptoms but also skin manifestations and associated comorbidities. This comprehensive strategy acknowledges the interconnected nature of psoriatic arthritis and strives for holistic care.

As the PsA treatment market continues to expand, challenges such as high costs of biologic therapies, accessibility issues, and long-term safety profiles remain important considerations. However, ongoing research and clinical trials are aimed at addressing these concerns and developing more cost-effective alternatives. Moreover, the advent of biosimilars—similar versions of approved biologics—offers the potential to increase treatment access and affordability.

Key Takeaways Psoriatic Arthritis (PsA) Treatment Market:

• Psoriatic Arthritis Overview: Psoriatic arthritis (PsA) is a chronic autoimmune disease that primarily affects individuals with psoriasis, a skin condition characterized by red, scaly patches. PsA involves joint inflammation, pain, and stiffness, often leading to joint damage if left untreated.
• Market Growth: The global market for psoriatic arthritis treatments has been growing steadily due to the increasing prevalence of psoriatic arthritis cases and the development of more targeted and effective therapies.
• Biologic Therapies: Biologic therapies have played a significant role in treating PsA. These are a class of medications designed to target specific components of the immune system that contribute to inflammation. Some commonly used biologics for PsA include TNF inhibitors (e.g., etanercept, adalimumab), IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., ustekinumab).
• Small Molecule Therapies: In addition to biologics, small molecule therapies have also been developed for PsA. These include Janus kinase (JAK) inhibitors such as tofacitinib, which target specific signaling pathways involved in inflammation.
• Combination Therapies: Some patients with PsA may benefit from combination therapies, which involve using different classes of medications together to achieve better control over inflammation and symptoms.
• Personalized Treatment: The approach to PsA treatment is becoming more personalized, taking into account factors such as the severity of symptoms, the extent of joint damage, and individual patient preferences. This allows for a more tailored and effective treatment plan.
• Pipeline Developments: The pharmaceutical industry continues to invest in research and development to bring new and innovative treatments to the market. New biologics, small molecule inhibitors, and disease-modifying antirheumatic drugs (DMARDs) are being explored to expand the treatment options available for PsA patients.

Get In Touch With Our Analyst To Resolve Any Doubts You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-2718

Key Companies Profiled:

• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• UCB S.A.
• Eli Lilly & Co
• Novartis AG
• Celgene Corporation
• AstraZeneca PLC

Psoriatic Arthritis (PsA) Treatment Market by Category:

Product Type:

• Non-steroidal Anti-inflammatory Drugs
• Disease Modifying Anti-rheumatic Drugs
  • Corticosteroids
  • Antimalarial
  • Methotrexate
  • Others
• Biologics
  • TNF Inhibitors
  • Interleukin Inhibitors

Route of Administration:

• Injectable
• Oral

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

Region:        

• North America
• Latin America
• Europe
• Oceania
• East Asia
• South Asia
• Middle East & Africa (MEA)

Personalized Solutions for Every Industry: Discover More in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-2718

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube